Červenka Luděk, Husková Zuzana, Kikerlová Soňa, Gawrys Olga, Vacková Šárka, Škaroupková Petra, Sadowski Janusz, Miklovič Matúš, Molnár Matej, Táborský Miloš, Melenovský Vojtěch, Bader Michael
Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
Hypertens Res. 2025 Jan;48(1):336-352. doi: 10.1038/s41440-024-01995-y. Epub 2024 Nov 13.
The aim of the present study was to assess systemic circulatory and tissue activities of both the classical arm and of the alternative arm of the renin-angiotensin system (RAS) in a new transgenic rat line (TG7371) that expresses angiotensin-(1-7) (ANG 1-7)-producing fusion protein; the results were compared with the activities measured in control transgene-negative Hannover Sprague-Dawley (HanSD) rats. Plasma and tissue concentrations of angiotensin II (ANG II) and ANG 1-7, and kidney mRNA expressions of receptors responsible for biological actions of ANG II and ANG 1-7 [i.e. ANG II type 1 and type 2 (AT and AT) and Mas receptors] were assessed in TG7371 transgene-positive and in HanSD rats. We found that male TG7371 transgene-positive rats exhibited significantly elevated plasma, kidney, heart and lung ANG 1-7 concentrations as compared with control male HanSD rats; by contrast, there was no significant difference in ANG II concentrations and no significant differences in mRNA expression of AT, AT and Mas receptors. In addition, we found that in male TG7371 transgene-positive rats blood pressure was lower than in male HanSD rats. These data indicate that the balance between the classical arm and the alternative arm of the RAS was in male TGR7371 transgene-positive rats markedly shifted in favor of the latter. In conclusion, TG7371 transgene-positive rats represent a new powerful tool to study the long-term role of the alternative arm of the RAS in the pathophysiology and potentially in the treatment of cardio-renal diseases.
本研究的目的是评估一种新的转基因大鼠品系(TG7371)中肾素-血管紧张素系统(RAS)经典途径和替代途径的全身循环及组织活性,该品系表达产生血管紧张素-(1-7)(ANG 1-7)的融合蛋白;并将结果与对照转基因阴性的汉诺威-斯普拉格-道利(HanSD)大鼠所测得的活性进行比较。在TG7371转基因阳性大鼠和HanSD大鼠中评估了血管紧张素II(ANG II)和ANG 1-7的血浆及组织浓度,以及负责ANG II和ANG 1-7生物学作用的受体的肾脏mRNA表达[即ANG II 1型和2型(AT1和AT2)受体以及Mas受体]。我们发现,与对照雄性HanSD大鼠相比,雄性TG7371转基因阳性大鼠的血浆、肾脏、心脏和肺中ANG 1-7浓度显著升高;相比之下,ANG II浓度无显著差异,AT1、AT2和Mas受体的mRNA表达也无显著差异。此外,我们发现雄性TG7371转基因阳性大鼠的血压低于雄性HanSD大鼠。这些数据表明,在雄性TGR7371转基因阳性大鼠中,RAS经典途径和替代途径之间的平衡明显向替代途径倾斜。总之,TG7371转基因阳性大鼠是研究RAS替代途径在心脏和肾脏疾病病理生理学以及潜在治疗中的长期作用的一种新的有力工具。